MYOV News and Press, Myovant Sciences Ltd. From 12/18/20

The FDA has announced it has granted the approval to Myovant Sciences (MYOV) for Orgovyx (relugolix) in the treatment of adult patients with advanced prostate cancer.Richard Pazdur, M.D., the Director of the FDA's Oncology Center of Excellence, said, “Today's approval marks t...

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: Evercore ISI 3 ...

BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 72 new employees with a grant date of November 15, 2...

Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) ...

The following slide deck was published by Myovant Sciences Ltd. in conjunction with their 2020 Q2 earnings call. For further details see: Myovant Sciences Ltd. 2020 Q2 - Results - Earnings Call Presentation

Myovant Sciences Ltd. (MYOV) Q2 2020 Earnings Conference Call November 12, 2020, 8:30 am ET Company Participants Ryan Crowe - VP, IR Lynn Seely - CEO Frank Karbe - President & CFO Adele Gulfo - Interim CCO Juan Camilo Arjona - CMO Conference Call Participants Jason Butler - JMP Securities...

FDA Priority Review of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer on track for decision by December 20, 2020 target action date NDA for relugolix combination tablet for uterine fibroids accepted for FDA review with a decision expecte...

As you know, Myovant's shares recently tumbled due to ambiguous Phase 3 data release for its prostate cancer franchise. Upon closer inspection, I believe that relugolix will ultimately be FDA-approved for prostate cancer. I expect relugolix to be FDA-approved for all big three ind...

Myovant has positive Phase 3 results in all 3 indications for its main drug relugolix. The stock has taken a huge dive based on disappointing results on a secondary endpoint of the relugolix Phase 3 prostate cancer trial. Nothing substantial has changed in my view since Myovant wa...

BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fisca...